Nasdaq Cprx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cantor Fitzgerald restated their overweight rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a report published on Friday, Benzinga reports. They currently have a $34.00 target price on the biopharmaceutical company’s stock. Several other equities research analysts also recently weighed in on CPRX. TheStreet raised shares of Catalyst Pharmaceuticals from a c+ […]

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a hold rating to a buy rating in a research note issued to investors on Thursday. A number of other brokerages have also recently commented on CPRX. Oppenheimer initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, December 21st. They […]

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a hold rating to a buy rating in a research note released on Thursday morning. Other research analysts also recently issued reports about the company. Citigroup started coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a buy rating […]

Clark Estates Inc. NY bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 188,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,198,000. Clark Estates Inc. NY owned 0.18% of Catalyst Pharmaceuticals […]

CenterBook Partners LP grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 20.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,577 shares of the biopharmaceutical company’s stock after acquiring an additional 2,259 shares during […]